Outlook Therapeutics Inc
OTLK.OQ- Latest Trade
- trading lower1.2USD
- Change
- -0.01
- % Change
0.83%Negative
- As of Aug 19 2022. Values delayed up to 15 minutes
- Day Range
- 1.16 - 1.24
- 52-Week Range
- 0.68 - 2.87
- Previous Close
- 1.21
- Open
- 1.21
- Volume
- 55,489.00
- 3 Month Average Trading Volume
- 18.88
- Shares Out (Mil)
- 226.14
- Market Cap
- 273.63
- Forward P/E
- -3.67
- Dividend Yield
- -99,999.99
Key Statistics
2 mean rating - 3 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- -99,999.99
- Price To Book (Quarterly)
- 13.61
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 52.19
- Long Term Debt/Equity (Quarterly)
- 0.04
- Return On Investment (TTM)
- -389.88
- Return On Equity (TTM)
- -182.21
2021 (millions USD)
About Outlook Therapeutics Inc (OTLK.OQ)
Company Information
Outlook Therapeutics, Inc. (Outlook) is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. ONS-5010, is the Company's product candidate, which is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. Its clinical program for ONS-5010 in wet AMD involves three clinical trials, which includes NORSE ONE, NORSE TWO and NORSE THREE. Outlook sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets for the treatment of wet AMD, diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).
Address
485 Route 1 South, Building F, Suite 320ISELIN, NJ
08830
United States
Industry
Business Services
Executive Leadership
- Ralph H. Thurman
- Independent Executive Chairman of the Board
- C. Russell Trenary
- President, Chief Executive Officer, Director
- Lawrence A. Kenyon
- Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
- Terry Dagnon
- Chief Operations Officer
- Alicia Tozier
- Senior Vice President - Marketing & Market Access
- Joel Prieve
- Senior Vice President - Commercial Operations
- Jeff Evanson
- Chief Commercial Officer
- Gerd Auffarth
- Independent Director
- Julian S. Gangolli
- Independent Director
- Yezan Munther Haddadin
- Independent Director
- Julia A. Haller
- Independent Director
- Kurt J. Hilzinger
- Independent Director
- Andong Huang
- Independent Director
- Faisal Ghiath Sukhtian
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,748.10 | 0.41%Negative |
| Copper | 673.80 | 0.45%Positive |
| Brent Crude Oil | 95.85 | 0.77%Negative |
| CBOT Soybeans | 1,490.75 | 0.32%Negative |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,228.48 | 1.29%Negative |
| Euro STOXX 50 | 3,730.32 | 1.25%Negative |
| FTSE 100 | 7,550.37 | 0.11%Positive |
| Nikkei 225 | 28,930.33 | 0.04%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes